Buy Mircette

Mircette

What Is Mircette?

Mircette is a combined oral contraceptive (COC) that contains the synthetic progestin desogestrel (0.15 mg) and the estrogen ethinyl estradiol (0.02 mg) in a single tablet. It is supplied as a pill and is classified under the women’s health therapeutic category. In the United Kingdom Mircette is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The product is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.

How Mircette Works in the Body

Mircette prevents pregnancy through several complementary mechanisms:

• Inhibition of ovulation - The estrogen component stabilises the endometrial lining, while desogestrel suppresses the luteinising hormone (LH) surge, preventing the release of an egg.
• Thickening of cervical mucus - Desogestrel makes cervical mucus more viscous, reducing sperm motility and entry.
• Endometrial alteration - The combined hormones create a less receptive uterine lining, decreasing the likelihood of implantation should fertilisation occur.

These actions begin after the first tablet is taken and become fully effective after seven consecutive days of correct use. The pill is rapidly absorbed, reaching peak plasma concentrations within a few hours. Desogestrel is metabolised primarily by the liver (CYP3A4) and has a half-life of approximately 30 hours, supporting once-daily dosing.

Conditions Treated by Mircette

Mircette is approved by the MHRA for the following indications:

• Primary prevention of pregnancy in women of reproductive age who are capable of becoming pregnant.
• Regulation of menstrual cycles, providing more predictable bleeding patterns and reducing dysmenorrhoea.
• Management of acne associated with hormonal fluctuations (off-label in the UK; see disclaimer).

The medication is intended for healthy women without contraindications listed below and is not suitable for emergency contraception.

Patient Suitability and Contraindications

Who Should Consider Mircette?

• Women aged 15 - 50 years seeking reliable, reversible contraception.
• Individuals who desire a regular menstrual cycle or have menstrual-related symptoms (e.g., heavy bleeding, painful periods).
• Patients who have no history of thromboembolic disease and are non-smokers (or smoke fewer than 15 cigarettes per day if under 35 years).

Absolute Contraindications

• Confirmed or suspected pregnancy.
• Current or past history of deep vein thrombosis, pulmonary embolism, or arterial thrombosis.
• Known or suspected estrogen-dependent neoplasia (e.g., breast cancer, endometrial cancer).
• Uncontrolled hypertension (≥ 160/100 mmHg).
• Severe liver disease (e.g., hepatitis, cirrhosis).
• Known hypersensitivity to desogestrel, ethinyl estradiol, or any excipients in the tablet.
• Women ≥ 35 years who smoke ≥ 15 cigarettes per day.

Relative Contraindications

• Migraine with aura.
• Diabetes with vascular complications.
• Gallbladder disease.
• Obesity (BMI > 35 kg/m²).
• Use of medications that increase the risk of clotting (e.g., certain antiretrovirals, hormonal therapy for other conditions).

Women in special populations should discuss risks with a healthcare professional:

• Pregnancy & lactation: Mircette must be stopped immediately if pregnancy is confirmed. It is not recommended during breastfeeding due to potential effects on milk production.
• Post-menopausal women: Not indicated; alternative hormone replacement therapy should be considered.
• Adolescents: Suitable after thorough evaluation of risk factors, especially smoking status.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Nausea or mild gastrointestinal upset - usually transient, may improve with food.
• Breast tenderness - tends to lessen after the first cycle.
• Headache - often mild; monitor if severe or persistent.
• Breakthrough bleeding or spotting - common during the first few months.
• Weight fluctuation - generally modest and not directly caused by the pill.

Serious Adverse Events

• Venous thromboembolism (VTE) - deep vein thrombosis or pulmonary embolism; seek urgent medical attention if leg pain, swelling, or shortness of breath occur.
• Arterial thrombosis - stroke or myocardial infarction; rare but fatal if symptoms such as sudden weakness, speech difficulty, or chest pain arise.
• Severe allergic reaction - rash, itching, swelling of face or throat; treat as an emergency.
• Liver dysfunction - jaundice, dark urine, severe abdominal pain; discontinue and contact a clinician promptly.

Drug Interactions

• CYP3A4 inducers (e.g., rifampicin, carbamazepine, St. John’s Wort) may reduce Mircette’s effectiveness → additional non-hormonal contraception is advised.
• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) can increase estrogen levels → monitor for signs of estrogen excess.
• Antifungal azoles (e.g., fluconazole) may increase plasma concentrations of ethinyl estradiol.
• Antiepileptic drugs (e.g., phenytoin, phenobarbital) may lower hormonal levels → consider dose adjustment or alternative contraceptive method.

Food and Lifestyle Interactions

• Alcohol - moderate consumption does not affect efficacy, but excessive intake may increase hepatic metabolism of hormones.
• Caffeine - no known interaction, but high intake can exacerbate headache.
• Grapefruit juice - not a significant effect on COC metabolism, yet caution is advised with other CYP3A4-modulating foods.
• Driving/Machinery - Mircette does not impair mental alertness; however, severe headache or dizziness should prompt temporary cessation of hazardous activities.

Note: Patients should disclose all prescription medicines, over-the-counter drugs, herbal supplements, and vitamins to their prescriber before starting Mircette.

How to Take Mircette

• Standard regimen: One tablet taken once daily, preferably at the same time each day, for 21 consecutive days followed by a 7-day hormone-free interval (no tablet). During the hormone-free days, a withdrawal bleed typically occurs.
• Missed dose: If a tablet is missed by less than 12 hours, take it as soon as remembered and continue with the next pill at the usual time. If more than 12 hours have passed, take the missed tablet immediately, discard any remaining tablets for that week, and start a new pack the following day-using a backup non-hormonal method (e.g., condoms) for the next 7 days.
• Overdose: Symptoms may include nausea, vomiting, severe abdominal pain, or breast tenderness. Seek urgent medical attention; treatment is supportive. No specific antidote exists.
• Discontinuation: Stopping Mircette may lead to return of ovulation within a few days. If cessation is planned, discuss transition to an alternative contraceptive method to avoid an unintended pregnancy.

Special Population Dosing Adjustments

• Renal or hepatic impairment: No routine dose reduction is required, but clinicians should evaluate risk and monitor closely.
• Elderly (> 50 years): Generally not prescribed due to increased thrombotic risk.

Monitoring and Follow-Up

• Blood pressure: Check at baseline and periodically, especially in women with a history of hypertension.
• Weight and BMI: Record at initiation; advise lifestyle measures if BMI exceeds 35 kg/m².
• Periodic review: At least annually, to reassess contraindications, smoking status, and overall tolerance.
• Laboratory tests: Not routinely required, but liver function tests may be ordered if hepatic disease is suspected.

Storage and Handling

• Keep tablets in the original blister pack until use.
• Store at room temperature (below 30 °C), away from direct sunlight and moisture.
• Keep out of reach of children; use child-proof containers where possible.
• Do not use tablets after the expiry date printed on the package. Dispose of unused pills according to local pharmacy waste guidelines.

Medication-Specific Glossary

Combined Oral Contraceptive (COC)

A single-tablet formulation that contains both an estrogen and a progestin to prevent pregnancy.

Desogestrel

A third-generation synthetic progestin that primarily suppresses ovulation and modifies cervical mucus.

Ethinyl Estradiol

A synthetic estrogen used in low doses to stabilise the endometrial lining and enhance contraceptive efficacy.

Thromboembolism

The formation of a blood clot (thrombus) that can travel through the bloodstream and block vessels (embolism), potentially causing serious events such as stroke or pulmonary embolism.

Medical Disclaimer

This article provides educational information about Mircette and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.